39 completed, 5 terminated, 4 unknown, 2 withdrawn. 53 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 53 | Completed 39, Terminated 5, Unknown 4, Withdrawn 2, Active not recruiting 1, Not yet recruiting 1, Recruiting 1 |
| Phase 2 | 5 | Completed 4, Unknown 1 |
Follow Filoviridae Infections: new trials by email Literature Review of Filoviridae Infections trials Research Report on Filoviridae Infections
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Investigate the Safety, Reactogenicity, and Immunogenicity of a Preventative Vaccine for Marburg Virus (mRNA-1519) in Healthy Adult Participants mRNA-1519, Placebo - Marburg Virus Disease (MVD) | Phase 1 | Not yet recruiting | ModernaTX, Inc. | 64 | 2026-11-02 | 2026-11-05 |
| A Clinical Study to Investigate the Safety and Immunogenicity of rVSV∆G-SUDV-GP, a Sudan Virus (SUDV) Vaccine for the Prevention of SUDV Disease in Adults in Good General Health rVSVΔG-SUDV-GP, Placebo - Sudan Virus Disease | Phase 1 | Recruiting | International AIDS Vaccine Initiative | 112 | 2026-05-08 | 2026-09-21 |
| A Clinical Trial to Evaluate the Safety and Immunogenicity of rVSV∆G-MARV-GP Vaccine in Adults in Good General Health rVSV∆G-MARV-GP, Placebo - Marburg Virus Disease | Phase 1 | Active not recruiting | International AIDS Vaccine Initiative | 112 | 2026-03-27 | 2026-10-30 |
| Study to Evaluate the Recombinant VSV (rVSV)-Marburg Virus Vaccine Candidate (PHV01) in Healthy Adult Subjects PHV01, Placebo - Marburg Virus Disease | Phase 1 | Completed | Public Health Vaccines LLC | 36 | 2024-02-05 | 2025-09-05 |
| A Study in Tanzania of a New Vaccine Against Two Types of Ebola ChAdOx1 biEBOV - Ebola | Phase 1 | Unknown | University of Oxford | 76 | 2022-03-30 | 2023-02-08 |
| A Study of a New Vaccine Against Two Types of Ebola ChAdOx1 biEBOV - Ebola | Phase 1 | Completed | University of Oxford | 26 | 2021-11-11 | 2025-04-04 |
| INO-4201 as Booster in Healthy VSV-ZEBOV Vaccinees INO-4201, Placebo - Ebola Virus Disease | Phase 1 | Completed | University of Geneva, Switzerland | 46 | 2021-09-01 | 2022-05-24 |
| Safety and Immunogenicity of the rVSVΔG-ZEBOV-GP Ebola Virus Vaccine Candidate in Children Living in Lambaréné, Gabon rVSVΔG-ZEBOV-GP, V920, Fibre and equilibrate breakfast and lunch, Active detection and treatment of pathogens - Ebola Virus Disease | Phase 1 / Phase 2 | Completed | Centre de Recherche Médicale de Lambaréné | 120 | 2021-04-09 | 2023-04-20 |
| An Open Study of the Safety and Pharmacokinetics of a Drug for the Emergency Prevention of Ebola Virus Disease Gamezumab - Ebola Virus Disease | Phase 1 | Unknown | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | 25 | 2021-02-15 | 2021-02-18 |
| Evaluation of Safety, Tolerability and Immune Responses of Ebola-S and Marburg Vaccines in Healthy Adults cAd3-Marburg, cAd3-EBO-S - Ebola Virus Disease, Marburg Virus Disease | Phase 1 | Completed | Albert B. Sabin Vaccine Institute | 32 | 2021-01-06 | 2022-08-03 |
| A Study to Evaluate the Single Dose Safety, Tolerability and Pharmacokinetics of IV BCX4430 galidesivir, placebo - Marburg Virus Disease | Phase 1 | Completed | BioCryst Pharmaceuticals | 32 | 2018-12-10 | 2021-07-23 |
| A Trial to Evaluate the Safety and Systems Biology Response of Ebolavirus Zaire Vaccine (ChAd3-EBO-Z) ChAd3-EBO-Z, MVA Multi-Filo Ebola Vaccine, Placebo - Ebola Disease, Immunisation | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 61 | 2018-11-12 | 2025-07-29 |
| cAd3-Marburg Vaccine in Healthy Adults cAd3-Marburg vaccine - Marburg Virus Disease | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 40 | 2018-10-09 | 2022-08-11 |
| Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-EBOMAB092-00-AB (MAb114), Administered Intravenously to Healthy Adults VRC-EBOMAB092-00-AB (MAb114) - Healthy Adult Immune Responses to Vaccine | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 19 | 2018-05-16 | 2020-10-26 |
| An Open Study of the Safety and Pharmacokinetics of a Medicinal Product for Emergency Prevention of Ebola GamEMab - Healthy | Phase 1 | Completed | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | 25 | 2018-03-12 | 2019-11-14 |
| Evaluating the Live-Attenuated Human Parainfluenza Virus Type 3 Vectored Vaccine Candidate Expressing Ebolavirus Zaire Glycoprotein as the Sole Envelope Glycoprotein HPIV3/ΔHNF/EbovZ GP vaccine, Placebo - Ebola Virus Disease | Phase 1 | Terminated | National Institute of Allergy and Infectious Diseases (NIAID) | 15 | 2018-03-05 | 2026-03-18 |
| A Double-blind Randomized Placebo-controlled Study of Safety and Immunogenicity of GamEvac-Lyo GamEvac-Lyo (component A), Placebo, GamEvac-Lyo (component B) - Healthy Volunteers | Phase 1 / Phase 2 | Completed | Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation | 220 | 2017-11-03 | 2019-11-14 |
| A Safety Trial to Test MVA-BN(R)-Filo and Ad26.ZEBOV Vaccines in Healthy Volunteers Ad26 Zaire Ebola Vaccine, MVA Multi-Filo Ebola Vaccine - Ebola Disease, Marburg Disease | Phase 1 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 65 | 2017-03-24 | 2025-07-29 |
| Trial to Evaluate Safety and Immunogenicity of an Ebola Zaire Vaccine in Healthy Adults Ebola Vaccine - low dose, Ebola Vaccine - mid dose, Ebola Vaccine - high dose - Ebola Virus Disease | Phase 1 | Completed | Auro Vaccines LLC | 38 | 2015-12-22 | 2017-04-04 |
| A Study to Assess Ebola Vaccines ChAd3-EBO-Z and Ad26.ZEBOV ChAd3-EBO-Z, Ad26.ZEBOV - Ebola Virus Disease | Phase 1 | Completed | University of Oxford | 32 | 2015-09-21 | 2018-04-11 |
Showing 20 of 53. Sign in to see all of them.
Hemorrhagic Fever, Ebola (46) · Marburg Virus Disease (11) · Hemorrhagic Fevers, Viral (9) · Virus Diseases (3) · RNA Virus Infections (2) · Acquired Immunodeficiency Syndrome (1) · Acquired angioedema (1) · Angioedemas, Hereditary (1) · Communicable Diseases (1) · Creutzfeldt-Jakob Syndrome (1) · Disseminated Intravascular Coagulation (1) · Hepatitis B (1) · Hepatitis C (1) · Infections (1)
Infections (52) · Mononegavirales Infections (52) · RNA Virus Infections (51) · Virus Diseases (50) · Hemorrhagic Fevers, Viral (44) · Animal Diseases (11) · Monkey Diseases (11) · Primate Diseases (11) · DNA Virus Infections (2) · Angioedema (1) · Blood Coagulation Disorders (1) · Blood-Borne Infections (1) · Brain Diseases (1) · Cardiovascular Diseases (1)
Saline Solution (4) · Ebola Vaccines (2) · ZMapp (2) · galidesivir (2) · AVI-7288 (1) · Atorvastatin (1) · Azithromycin (1) · Chickenpox Vaccine (1) · Dietary Fiber (1) · Erlotinib Hydrochloride (1) · Fluid Therapy (1) · Injections (1) · Irbesartan (1) · Lunch (1) · Sunitinib (1)
National Institute of Allergy and Infectious Diseases (NIAID) (16) · University of Oxford (7) · Sarepta Therapeutics, Inc. (4) · Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation (3) · Arbutus Biopharma Corporation (2) · BioCryst Pharmaceuticals (2) · International AIDS Vaccine Initiative (2) · Jiangsu Province Centers for Disease Control and Prevention (2) · University of Maryland, Baltimore (2) · Albert B. Sabin Vaccine Institute (1) · Auro Vaccines LLC (1) · Centre Hospitalier Universitaire Vaudois (1) · Centre de Recherche Médicale de Lambaréné (1) · Cerus Corporation (1) · Clinical Research Management, Inc. (1)
United States (27) · United Kingdom (6) · China (3) · Russia (3) · Mali (2) · Switzerland (2) · Uganda (2) · Australia (1) · Gabon (1) · Germany (1) · Guinea (1) · Kenya (1) · Liberia (1) · Senegal (1) · Sierra Leone (1)
Alison Heald, MD (3) · Richard T Davey, M.D. (3) · Julie E Ledgerwood, D.O. (2) · Kawsar Talaat, MD (2) · Adrian V Hill (1) · Angela Huttner, MD (1) · Apinya B Vutikullird, MD (1) · Blaise Genton, MD PhD (1) · Christopher Woods, MD, MPH (1) · Daniel Dickerson, MD, PhD (1) · David Hoover, MD (1) · David L Hoover, MD (1) · Dmitry Lyoznov, MD, PhD (1) · Emanuel DeNoia, MD (1)
PMID 25426834, PMID 25830326, PMID 26546548, PMID 26659569, PMID 28017642, PMID 28647166, PMID 30407513, PMID 35182042, PMID 1538192, PMID 15577929, PMID 16375711, PMID 25225676, PMID 25540891, PMID 25629663, PMID 25817373, PMID 26200980, PMID 26725450, PMID 26768569, PMID 27004234, PMID 27732819, PMID 28434944, PMID 28708962, PMID 29627147, PMID 30452666, PMID 30686586, PMID 30891607, PMID 31952923, PMID 32129478, PMID 36709074, PMID 39715748, PMID 39922207, PMID 41610955, PMID 8237108
2014 (1), 272201300017C-18-0-1 (1)